证券代码：002294 证券简称：信立泰 深圳信立泰药业股份有限公司 独立董事提名人声明与承诺 提名人深圳信立泰药业股份有限公司董事会现就提名刘来平为 深圳信立泰药业股份有限公司第六届董事会独立董事候选人发表公 开声明。被提名人已书面同意作为深圳信立泰药业股份有限公司第六 届董事会独立董事候选人（参见该独立董事候选人声明）。本次提名 是在充分了解被提名人职业、学历、职称、详细的工作经历、全部兼 职、有无重大失信等不良记录等情况后作出的，本提名人认为被提名 人符合相关法律、行政法规、部门规章、规范性文件和深圳证券交易 所业务规则对独立董事候选人任职资格及独立性的要求，具体声明并 承诺如下事项： 一、被提名人已经通过深圳信立泰药业股份有限公司第五届董事 会提名委员会或者独立董事专门会议资格审查，提名人与被提名人不 存在利害关系或者其他可能影响独立履职情形的密切关系。 是 □否 如否，请详细说明：______________________________ 二、被提名人不存在《中华人民共和国公司法》第一百四十六条 等规定不得担任公司董事的情形。 是 □否 如否，请详细说明：_____________________ ...

深圳信立泰药业股份有限公司 董事会提名委员会关于公司有关事项所发表的审查意见 根据《中华人民共和国公司法》、《深圳证券交易所股票上市规则》、《深 圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》以及 《深圳信立泰药业股份有限公司章程》等有关规定，作为深圳信立泰药业股份有 限公司（下称"公司"）董事会提名委员会成员，在认真审阅了有关资料后，发 表审查意见如下： 1、经审阅董事候选人的相关材料，我们认为董事候选人具备担任公司董事 的资格和能力，不存在《公司法》、《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》和《公司章程》等规定不得担任公司董事的情 形，不存在被证券交易场所公开认定不适合担任上市公司董事、监事和高级管理 人员，且期限尚未届满的情形，不存在被中国证监会采取不得担任上市公司董事、 监事、高级管理人员的证券市场禁入措施，且期限尚未届满的情形。 王学恭 刘来平 叶澄海 深圳信立泰药业股份有限公司 2、我们同意提名叶宇翔、叶澄海、颜杰、沈清、陈茜渝、杨健锋、朱厚佳、 刘来平、王学恭为第六届董事会董事候选人，其中朱厚佳、刘来平、王学恭为独 立董事候选人，并同意提交公 ...

声明人 刘来平 作为深圳信立泰药业股份有限公司第六届董事 会独立董事候选人，已充分了解并同意由提名人深圳信立泰药业股份 有限公司董事会提名为深圳信立泰药业股份有限公司（以下简称该公 司）第六届董事会独立董事候选人。现公开声明和保证，本人与该公 司之间不存在任何影响本人独立性的关系，且符合相关法律、行政法 规、部门规章、规范性文件和深圳证券交易所业务规则对独立董事候 选人任职资格及独立性的要求，具体声明并承诺如下事项： 一、本人已经通过深圳信立泰药业股份有限公司第五届董事会提 名委员会或者独立董事专门会议资格审查，提名人与本人不存在利害 关系或者其他可能影响独立履职情形的密切关系。 是 □否 如否，请详细说明：_____________________________ 深圳信立泰药业股份有限公司 独立董事候选人声明与承诺 三、本人符合中国证监会《上市公司独立董事管理办法》和深圳 证券交易所业务规则规定的独立董事任职资格和条件。 是 □否 如否，请详细说明：______________________________ 四、本人符合该公司章程规定的独立董事任职条件。 是 □否 如否，请详细说明：__________ ...

近日，深圳信立泰药业股份有限公司（下称"公司"）收到子公司深圳市科 奕顿生物医疗科技有限公司（下称"科奕顿"）通知，其自主研发的"腔静脉滤 器系统"（SaExten®）获得国家药品监督管理局的注册批准。现就相关信息公告 如下： 一、产品基本信息 产品名称：腔静脉滤器系统 适用范围：该产品通过经股静脉或经颈静脉入路经皮置入，用于预防下腔静 脉系统栓子脱落而引起的肺动脉栓塞（PE）。 注册证编号：国械注准 20233131135 证券代码：002294 证券简称：信立泰 编号：2023-039 深圳信立泰药业股份有限公司 关于子公司腔静脉滤器系统 获得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 SaExten®滤器采用创新设计，具有优越的居中性、易回收性和长回收时间窗 等性能。SaExten®滤器作为新型长回收时间窗的可回收滤器，在临床症状达到回 收指征时可实现安全回收。 SaExten®注册临床试验选择巴德 DENALI 滤器为对照。基于注册临床试验中 有效性指标及安全性指标数据，可认为科奕顿生产的 SaExten®腔静脉滤器系统在 预 ...

深圳信立泰药业股份有限公司 关于选举职工代表监事的公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 深圳信立泰药业股份有限公司（下称"公司"）第五届监事会任期届满，根 据《公司法》、《公司章程》等有关规定，公司第六届监事会将由三名监事组成， 其中一名为职工监事，由公司职工通过职工代表大会、职工大会或者其他形式民 主选举产生。 证券代码：002294 证券简称：信立泰 编号：2023-038 公司于 2023 年 8 月 9 日召开职工代表大会，对第六届监事会职工监事代表 人选进行选举，会议由工会主席唐吉主持，23 名职工代表参加了本次会议。 经职工代表大会认真审议，会议以举手表决的方式，一致通过并选举李扬兵 先生为公司第六届监事会职工代表监事（简历附后），并将与公司股东大会选举 产生的 2 名监事共同组成第六届监事会，任期与第六届监事会一致。 上述职工代表监事的选举程序和任职资格符合《公司法》、《深圳证券交易 所股票上市规则》、《深圳证券交易所上市公司自律监管指引第 1 号——主板上 市公司规范运作》等法律法规、规范性文件及《公司章程》等规定，单一股东提 ...

Group 1: Company Overview - Shenzhen Xinlitai Pharmaceutical Co., Ltd. has recently received approval for its small molecule drug, Ennaruo, aimed at treating renal anemia [1] - The company is focusing on market access, health insurance negotiations, and hospital admissions for Ennaruo [1] - A dedicated sales team of approximately 50-100 personnel is planned to be established to promote Ennaruo [2] Group 2: Research and Development Progress - The company plans to submit an IND application to the FDA for the S086 project targeting hypertension [1] - The JK07 project is expected to enter Phase II clinical trials in the U.S. by Q4 of this year [1] - The SAL0130 project is currently initiating Phase III clinical trials, while the SAL056 project has completed patient enrollment for Phase III [2] Group 3: Market Potential and Growth Drivers - The number of hypertension patients is substantial, with a significant awareness gap [2] - The company has achieved its promotion goals in major hospitals and is expanding efforts to grassroots and community hospitals [2] - Ennaruo is positioned as a first-in-class HIF-PHI drug in China, with advantages such as once-daily oral administration and low drug interaction risks [2] Group 4: Financial Outlook - The next two years are expected to see stable revenue growth due to new product launches and increased marketing expenditures [2] - The company anticipates a gradual market entry for new products over the next 2-3 years, contributing to its high-quality development [2]

Financial Performance - The company's operating revenue for Q1 2023 was ¥887,511,571.76, a decrease of 5.10% compared to the same period last year[4] - Net profit attributable to shareholders for Q1 2023 was ¥210,947,894.80, down 11.15% year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 4.55% to ¥190,290,710.43[4] - Basic and diluted earnings per share for Q1 2023 were both ¥0.190, a decline of 13.64% compared to the previous year[5] - Net profit for Q1 2023 was CNY 208.70 million, a decline of 11.9% compared to CNY 236.86 million in Q1 2022[25] - Total operating revenue for Q1 2023 was CNY 887.51 million, a decrease of 5.1% from CNY 935.24 million in Q1 2022[24] Cash Flow - The net cash flow from operating activities decreased by 24.13% to ¥125,382,415.26[4] - The net cash flow from operating activities for Q1 2023 was ¥125,382,415.26, a decrease of 24.1% compared to ¥165,268,064.55 in Q1 2022[28] - Total cash inflow from investment activities was ¥231,202,677.37, significantly higher than ¥70,204,353.49 in the same period last year[28] - The net cash flow from investment activities was -¥237,575,476.00, worsening from -¥161,096,553.94 year-over-year[28] - Cash inflow from financing activities totaled ¥35,800,000.00, down from ¥138,200,000.00 in Q1 2022[28] - The net cash flow from financing activities was -¥121,780,139.49, slightly improved from -¥126,432,488.64 in the previous year[28] - The company reported a total cash outflow from operating activities of ¥773,742,612.99, compared to ¥738,786,646.75 in the previous year[28] Assets and Liabilities - Total assets at the end of the reporting period were ¥9,670,530,091.05, a decrease of 0.87% from the end of the previous year[5] - The total current liabilities decreased to ¥1,319,341,733.38 from ¥1,603,635,828.99, a decline of about 17.7%[22] - The company's total liabilities decreased to ¥1,319,341,733.38, down from ¥1,603,635,828.99, indicating a reduction of about 17.7%[22] - Total equity attributable to shareholders increased to CNY 8,151.06 million, up from CNY 7,940.88 million in the previous year[25] Investments and Financial Management - The company reported a significant increase in trading financial assets, up 31.95% to ¥104,925,000[9] - The company has engaged in high-risk entrusted financial management, with a total amount of RMB 145,179.02 million in various financial products[16] - The company reported a total of RMB 50.44 million in actual gains from entrusted financial management during the reporting period[18] - The company has plans for future entrusted financial management, indicating ongoing investment strategies[18] - The company has no changes in the investment projects funded by the raised capital and no external transfer or replacement of these projects[14] Shareholder Information - Shareholders' equity attributable to the parent company increased by 2.65% to ¥8,151,063,802.50[5] - The company has a total of 635,279,380 shares held by its largest shareholder, accounting for a significant portion of the total share capital[12] - The company has no known related party transactions or agreements among its top shareholders during the reporting period[12] Other Financial Metrics - The company received government subsidies amounting to ¥21,910,949.26 during the reporting period[7] - The cash paid for the acquisition of fixed assets, intangible assets, and other long-term assets was ¥102,873,451.16, a decrease from ¥172,774,463.43 in Q1 2022[28] - The cash received from investment recoveries was ¥229,254,473.23, a significant increase from ¥70,000,000.00 in the same quarter last year[28] - The impact of exchange rate changes on cash and cash equivalents was -¥7,728,050.87, compared to -¥985,060.33 in Q1 2022[28]

证券代码：002294 证券简称：信立泰 深圳信立泰药业股份有限公司投资者关系活动记录表 编号：20230414 | | □特定对象调研 □分析师会议 | | --- | --- | | 投 资 者 关 | □媒体采访 √业绩说明会 | | 系 活 动 类 | □新闻发布会 □路演活动 | | 别 | □现场参观 | | | □其他（请文字说明其他活动内容） | | 活 动 参 与 | 2022 年年度业绩说明会参与者 | | 人员 | | | 时间 | 年 月 日 2023 4 14 | | 地点 | 线上会议 | | 形式 | 网络远程方式 | | 上 市 公 司 | 董事、总经理颜杰，独立董事王学恭，财务负责人孔芸，董事、董 | | 接 待 人 员 | 事会秘书杨健锋 | | 姓名 | | | | 主要交流内容： | | | 1、 2022 年度信立坦销售额大概是多少？ | | | 答：您好！相关数据未公开，就信立坦来看，受去年 月份 12 | | 交 流 内 容 | 疫情影响，比预期略少一些，今年相信会有不错的增长，谢谢！ | | 及 具 体 问 | | | 答记录 | 2、 07 一期揭盲大概什么时 ...

证券代码：002294 证券简称：信立泰 编号：2023-022 深圳信立泰药业股份有限公司 本次网上业绩说明会将采用网络文字互动的方式举行，投资者可于 2023 年 4 月 14 日（星期五）15:00-17:00 通过网址 https://eseb.cn/13HOQ5zw0qA 或使用 微信扫描下方小程序码即可进入参与互动交流。 为广泛听取投资者的意见和建议，公司提前向投资者征集问题，投资者可于 2023 年 4 月 14 日前进行会前提问，公司将通过本次业绩说明会，在信息披露允 许范围内就投资者普遍关注的问题进行回答。 出席本次说明会的人员有：董事、总经理颜杰先生，独立董事王学恭先生， 财务负责人孔芸女士，董事、董事会秘书杨健锋先生。 欢迎广大投资者积极参与！ 关于举行 2022 年年度业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 深圳信立泰药业股份有限公司（下称"公司"）《2022 年年度报告》、《2022 年年度报告摘要》已于 2023 年 3 月 29 日披露。 为便于广大投资者进一步了解公司 2022 年度经营情况等，公司将于 ...

Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB in 2022, representing a growth of 20% compared to the previous year[10]. - The company's operating revenue for 2022 was ¥3,482,011,378.10, representing a 13.85% increase from ¥3,058,392,041.37 in 2021[16]. - Net profit attributable to shareholders for 2022 was ¥636,943,594.06, a 19.34% increase from ¥533,726,576.95 in 2021[16]. - The net profit after deducting non-recurring gains and losses for 2022 was ¥551,815,169.06, showing a significant increase of 94.77% compared to ¥283,309,767.44 in 2021[16]. - The company achieved a revenue of 3.482 billion yuan in 2022, representing a year-on-year growth of 13.85%[25]. - The company reported a total of ¥85,128,425.00 in non-recurring gains for 2022, down from ¥250,416,809.51 in 2021[21]. - The company’s cash flow from operating activities for 2022 was ¥970,804,863.11, a decrease of 18.07% from ¥1,184,978,525.65 in 2021[16]. - The company’s total sales expenses increased by 5.65% to ¥1,094,427,270.13 compared to the previous year[48]. - The company’s total profit available for distribution to investors in 2022 was CNY 5,002,893,148.11, with a cash dividend distribution of CNY 545,679,506.00, representing 128.73% of the net profit attributable to ordinary shareholders[170]. Research and Development - The company has approximately 60 innovative products in the research and development pipeline, with some at a globally leading level[7]. - Research and development investments increased by 30% in 2022, focusing on innovative drug formulations and advanced technologies[10]. - The company is focusing on innovative drug development, particularly in the fields of cardiovascular and chronic disease management, aligning with national health strategies[23]. - The company has submitted 6 new drug IND applications and 2 new product registration applications during the reporting period[28]. - The company achieved a total R&D investment of approximately ¥917.50 million in 2022, representing a year-on-year increase of 32.69% from ¥691.48 million in 2021[59]. - The number of R&D personnel increased by 18.15% to 755 in 2022, compared to 639 in 2021, with the proportion of R&D staff rising from 19.75% to 21.86%[58]. - The company has received 28 new patent authorizations in 2022, including 22 invention patents and 6 utility model patents, enhancing its intellectual property portfolio[57]. - The company is advancing multiple research and development projects across various stages, including 14 chemical drug projects and 6 biological drug projects[51]. Market Expansion and Product Development - The company plans to launch around two innovative products each year, including recent products with significant efficacy and safety advantages[7]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2023[10]. - The company aims to enhance its market position by expanding its product offerings in cardiovascular and orthopedic treatments, leveraging its research capabilities[24]. - The company is focusing on expanding its product lines in cardiovascular, diabetes, orthopedics, oncology, and anti-infection areas[89]. - The company is pursuing an IPO for its medical device segment and plans to seek overseas financing for global product development[91]. - The company plans to achieve 2 NDA submissions and 3 IND applications for innovative products in 2023, enhancing its product pipeline[91]. - The company is actively participating in national drug procurement, which has provided stable cash flow and operational improvements[30]. Strategic Initiatives and Acquisitions - A strategic acquisition of a biotech firm was completed, enhancing the company's capabilities in drug development and increasing its product pipeline[10]. - The company is considering strategic acquisitions to enhance its product portfolio, with a target of identifying at least two potential acquisition candidates by mid-2023[143]. - The company has established partnerships with three major hospitals to facilitate clinical trials for new drugs, aiming to expedite the approval process[10]. Risk Management and Challenges - The company acknowledges potential risks such as R&D failures and policy changes that could impact pricing and costs[3]. - The company is facing risks related to R&D failures, policy changes affecting drug pricing, and rising costs of raw materials and labor[93][94]. - The company has established comprehensive internal control and risk management systems to mitigate market, liquidity, credit, operational, and legal risks associated with derivative investments[74]. Corporate Governance and Shareholder Engagement - The company has continuously improved its corporate governance structure and internal control systems[97]. - The company held two shareholder meetings during the reporting period, ensuring equal rights for all shareholders, especially minority shareholders[102]. - The company has established a transparent decision-making process for profit distribution, ensuring that minority shareholders have the opportunity to express their opinions[168]. - The company has a well-structured board with independent directors fulfilling their supervisory roles[104]. - The company has implemented various management systems to ensure compliance and transparency in operations[98]. Sustainability and Environmental Compliance - The company emphasizes sustainable development and aims to maximize shareholder and company interests[97]. - The company has been recognized as a key pollutant discharge unit by local environmental protection authorities, with its manufacturing plants adhering to strict environmental standards[195]. - The company has implemented various environmental protection measures, including the establishment of a "Safety Production Committee" and dedicated HSE management teams across its subsidiaries[195]. - The company complies with multiple environmental laws and standards, ensuring stable operation of its waste treatment facilities[196]. Employee Management and Development - The company has implemented a training program that includes various levels of training for employees, enhancing management capabilities and professional skills[162]. - The company emphasizes the importance of talent development, providing resources and platforms for employee growth and supporting the establishment of a talent reserve[162]. - The company has implemented a second employee stock ownership plan, significantly enhancing the motivation and retention of key employees[160]. - The total number of employees at the end of the reporting period was 3,454, with 2,344 in the parent company and 1,110 in major subsidiaries[158].